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INTRODUCTION
The crucial role of severe disturbances in intracellular ionic
homeostasis (including changes in [Na+]i, [K+]i, [H+]i, [Ca2+]i) in
the initiation and progression of potentially lethal cardiac
arrhythmias has been demonstrated in a wide range of
experimental and clinical studies (1). These arrhythmias have
poor prognosis and a high rate of mortality, primarily due to their
complex and not fully understood pathomechanisms and the
consequent sub-optimal medical treatment (2).
An important component of the underlying mechanisms is
an increase in the activity of sarcolemmal Na+ /H+ (NHE) and
Na+/Ca2+ (NCX) exchangers (3, 4). During myocardial
ischaemia the aerobic energy metabolism of the heart is
compromised. A pathological consequence of the anaerobic shift
is intracellular acidosis. Simultaneous inactivation of the
Na+/K+-ATPase (NKA) and activation of the NHE leads to
gradual [Na+]i accumulation, which, in turn, shifts the NCX into
reverse transport mode, generating a marked elevation in [Ca2+]i
(5). During the early phase of reperfusion, the NHE becomes
fully activated and [Na+]i accumulation is further accelerated.
The reverse transport activity of NCX is also highly enhanced
and severe [Ca2+]i overload, the most important factor in
generation of post-ischaemic arrhythmias and hypercontracture,
may build up (6).
A reasonable defensive strategy to limit the
ischaemia/reperfusion-induced [Na+]i accumulation and
subsequent [Ca2+]i overload seems to be a pharmacological
inhibition of one or both exchangers. However, since their
normal activity is vital, only a partial and temporal blockade
may be safely introduced. In preclinical studies, NHE inhibition
has been shown to be highly effective, especially when applied
before ischaemia (7-10). Based on the promising results of these
studies, NHE inhibition has been suggested as a straightforward
therapeutic strategy against ischaemia-reperfusion-induced
cardiac injuries. Human results from phase2/phase3 clinical
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During ischaemia/reperfusion, the rise in [Na+]i, induced by simultaneous depression of the Na+/K+-ATPase and
activation of the Na+/H+ exchanger (NHE), shifts the Na+/Ca2+ exchanger (NCX) into reverse transport mode, resulting
in Ca2+i overload, which is a critical factor in enhancing the liability to cardiac arrhythmias. The inhibition of NHE, and
recently NCX has been suggested to effectively protect the heart from reperfusion-induced arrhythmias. In this study,
we investigated and compared the efficacy of individual or the simultaneous inhibition of the NHE and NCX against
reperfusion-induced arrhythmias in Langendorff-perfused rat hearts by applying a commonly used regional ischaemia-
reperfusion protocol. The NHE and NCX were inhibited by cariporide and SEA0400 or the novel, more selective ORM-
10103, respectively. Arrhythmia diagrams calculated for the reperfusion period were analysed for the incidence and
duration of extrasystoles (ESs), ventricular tachycardia (VT) and ventricular fibrillation (VF). NHE inhibition by
cariporide was highly efficient in reducing the recorded reperfusion-induced arrhythmias. Following the application of
SEA0400 or ORM-10103, the number and duration of arrhythmic periods were efficiently or moderately decreased.
While both NCX inhibitors effectively reduced ESs, the most frequently triggered arrhythmias, they exerted limited or
no effect on VTs and VFs. Of the NCX inhibitors, ORM-10103 was more effective. Surprisingly, the simultaneous
inhibition of the NCX and NHE failed to significantly improve the antiarrhythmic efficacy reached by NCX blockade
alone. In conclusion, although principal simultaneous NHE+NCX inhibition should be highly effective against all types
of the recorded reperfusion-induced arrhythmias, NCX inhibitors, alone or in combination with cariporide, seem to be
moderately suitable to provide satisfactory cardioprotection - at least in the present arrhythmia model. Since ORM-
10103 and SEA0400 are known to effectively inhibit after-depolarisations, it is suggested that their efficacy and that of
other NCX inhibitors may be higher and more pronounced in the predominantly Ca2+i-dependent triggered arrhythmias.
K e y  w o r d s : isolated heart, ischaemia-reperfusion injury, arrhythmia, Na+/Ca2+ exchanger, Na+/H+ exchanger, cariporide,
extrasystole, ventricular tachycardia
trials (GUARDIAN, EXPEDITION, ESCAMI), however,
produced disappointing results, reporting only limited efficacy
of this strategy in the majority of cases (11).
Theoretically, NCX inhibitors administered shortly after the
onset of a heart attack might reduce the probability of arrhythmia
generation by limiting damage in the border zone. In a range of
preclinical studies, especially under moderate ischaemia, reverse
mode inhibition of NCX has been found to suppress both [Na+]i
and [Ca2+]i overload, hypercontracture, enzyme release and cell
damage (12). Consequently, the inhibition of NCX may have
substantial therapeutic potential in the prevention of cardiac
ischaemia/reperfusion-induced arrhythmias and injuries (13).
Evaluation of the experimental data on NCX inhibition was,
however, seriously hampered by the lack of selective and highly
effective NCX inhibitors. This may explain why only NHE
inhibitors are used to some extent in clinical practice. NCX
inhibitors have never been tested in clinical trials.
In summary, there is convincing evidence suggesting that in
clinical practice, NHE inhibition, per se, fails to prevent or
substantially reduce ischaemia/reperfusion-induced
arrhythmogenesis (14). On the other hand, reverse mode NCX
inhibition displayed promising cardioprotective effects in animal
studies (15). The present work was based on the assumption, that
since the enhanced NHE activity is only one - although probably
the most important - factor resulting in cardiac arrhythmogenesis
due to the subsequent [Ca2+]i overload, the inhibition of NHE
itself, does not seem to be the optimal treatment to reduce the
incidence and severity of cardiac arrhythmias. One may also
speculate that since the NHE and NCX seem to play a joint key
role in the induction of ischaemia/reperfusion-induced [Ca2+]i
overload, the deteriorative effects might be better attenuated by
simultaneously inhibiting both the NHE and NCX. Therefore,
the primary goal of the present study was to evaluate and
compare the putative protective effects of individual or
combined inhibition of NHE and NCX against post-ischaemic
arrhythmias, at least partially caused by the reperfusion-induced
[Ca2+]i-overload. For this purpose, a well-known, well-
characterised NHE inhibitor, cariporide (16), and two NCX
inhibitors, the fairly selective SEA0400 (17) and the novel, more
selective ORM-10103 (18), were used.
METHODS AND MATERIALS
All experiments were performed in compliance with the
Guide for the Care and Use of Laboratory Animals (USA NIH
publication No. 86-23 revised 1996) and fully conformed to
Directive 2010/63/EU of the European Parliament. Experimental
protocols were approved by the Ethics Committee for the
Protection of Animals in Research of the University of Szeged,
Szeged, Hungary (permit No. I-74-9/2009).
Preparation of isolated hearts
120 male Sprague-Dawley rats (250–350 g) were
anaesthetised with sodium thiopental (0.1 g/kg, i.p.) and injected
with heparin sodium (500 IU i.v.). Hearts were rapidly excised,
mounted via the aorta on a Langendorff apparatus and perfused
retrograde with warm (37°C), modified Krebs-Henseleit
bicarbonate (KHB) buffer at a constant pressure (80 mmHg).
The KHB solution contained (in mmol/l): NaHCO3 25; KCl 4.3;
NaCl 118.5; MgSO4 1.2; KH2PO4 1.2; Na-pyruvate 5; glucose
11; CaCl2 2, having a pH of 7.4±0.05 when gassed with
carbogene (95% O2 + 5% CO2). For the induction of regional
ischaemia, a 6/0 braided silk suture was placed around the left
anterior descending coronary artery (LAD). A water-filled latex
balloon was inserted into the left ventricular cavity and inflated
to obtain a control state end-diastolic pressure (LVEDP) of 4–8
mmHg. Coronary flow (CF), left ventricular pressure (LVP),
perfusion pressure, and the electrocardiogram (ECG) were
simultaneously recorded using the Haemosys software
(Experimetria, Hungary). Left ventricular contractility
(±dP/dtmax) and heart rate (HR) were calculated off-line from the
recorded LVP curve.
Experimental protocol
All hearts were allowed to stabilise for 10 min. The
perfusion of drugs or vehicle started 5 minutes before occlusion
of the left anterior descending coronary artery (LAD) and were
maintained throughout the protocol. Hearts were randomly
assigned into six experimental groups: the control (CON) group
was perfused with KHB solution containing solely the vehicle
(dimethyl sulphoxide (DMSO) in 0.01% final concentration).
Three heart groups were perfused with KHB solution containing
only a single inhibitor: 5 µM cariporide (CAR); 1 µM SEA0400
(SEA) or 1 µM ORM-10103 (ORM). Two experimental groups
were treated with a combination of the NHE and NCX
inhibitors: 5 µM cariporide + 1 µM SEA0400 (SEA+CAR) or
with 5 µM cariporide + 1 µM ORM-10103 (ORM+CAR).
Ischaemia-reperfusion-induced arrhythmias were evoked by
pulling on the suture around the artery for 10 minutes.
Successful occlusion was confirmed by a significant reduction in
coronary flow. To ensure the homogeneity of ischaemic damage
and to exclude possible bias due to surgical artefacts, hearts with
a more than 65% decrease in coronary flow rate were excluded
from the study. Furthermore, hearts developing severe
arrhythmias during the ischaemic period were also excluded.
The 10 min period of regional ischaemia was followed by 30
min reperfusion initiated via releasing the suture. Successful
reperfusion was confirmed by an immediate increase in coronary
flow. LVP and ECG were recorded and analysed off-line for
duration and incidence of the sinus rhythm periods (SR), SR
periods with multiple extrasystoles (ES), periods of ventricular
tachycardia (VT), defined by the incidence of four or more
consecutive ventricular premature beats. The onset of ventricular
fibrillation (VF) was verified by the permanent lack of
individual QRS deflections.
Drugs
SEA0400 and cariporide were synthesised in the Department
of Pharmaceutical Chemistry, University of Szeged. ORM-
10103 was a gift from Orion Pharma (Espoo, Finland). The
inhibitory effect of both inhibitors is bidirectional with nearly
symmetrical concentration dependency for the reverse and
forward transport modes. All three drugs were dissolved in
dimethyl-sulphoxide (DMSO) and diluted in KHB until
establishing the final concentration. The DMSO concentrations
in the stock solutions and in the final perfusion solution were 5%
and 0.01%, respectively. At this final concentration, the effect of
DMSO on the heart is generally considered negligible.
Data processing and statistical analysis
Major haemodynamic parameters (CF, HR, LVSP, LVEDP,
DP and ±dP/dtmax) were either directly measured or calculated
from the pressure recording (LVP curve) four times during the
experiment: at the end of the equilibration (control), pre-
treatment, ischaemic and reperfusion periods, respectively. All
haemodynamic values calculated for the reperfusion phase and
summarised in Table 1 were obtained from hearts devoid of
sustained arrhythmias or were evaluated during a period of sinus
rhythm between two arrhythmic periods.
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The severity of reperfusion-induced arrhythmias observed in
the LVP and ECG recordings was judged by evaluating three
crucial arrhythmia-related variables: the type of arrhythmic activity
(i.e. extrasystoles (ES), ventricular tachycardia (VT) and
ventricular fibrillation (VF)) and the incidence and duration of time
periods with that arrhythmia type. Furthermore, total duration of
the regular sinus rhythm periods (SR) was also calculated. It should
be emphasised that although transient and sustained ventricular
fibrillatory periods were both observed during the 30 min
reperfusion period, since we were primarily interested in the
efficiency of the applied pharmacological treatments against
ventricular arrhythmias generated during the early phase of
reperfusion, these two forms of VF were not separated during
evaluation of the individual arrhythmia diagrams.
Since in many of the hearts subjected to the regional
ischaemia/reperfusion protocol the ventricular fibrillation, if
started, became sustained - probably, but not necessarily
reflecting ischaemia-reperfusion-induced irreversible shifts in
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 Control Pretreat Ischemia Reperfusion 
CF (ml/min)       
CON 17 ± 0.9 17 ± 1.0   9 ± 0.9 * 15 ± 1.4  
CAR  19 ± 1.5 18 ± 1.5 13 ± 1.8 * 16 ± 2.3  
SEA 16 ± 0.8 16 ± 1.1 10 ± 1.4 * 14 ± 1.3  
ORM 16 ± 1.1 17 ± 1.1   9 ± 0.9 * 15 ± 1.5  
SEA + CAR 16 ± 1.4 15 ± 1.3   9 ± 1.1 * 13 ± 1.6  
ORM + CAR 20 ± 0.9 20 ± 1.1 11 ± 1.3 * 16 ± 1.3 § 
 HR (beats/min)         
CON 313 ± 11 295 ± 10 280 ± 12 * 277 ± 12 § 
CAR  325 ± 13 320 ± 11 310 ± 12  280 ± 14 § 
SEA 297 ± 10 301 ± 11 294 ± 12  281 ± 20 § 
ORM 311 ± 12 308 ± 12 302 ± 12  303 ± 19 § 
SEA + CAR 303 ± 15 288 ± 21 287 ± 18  308 ± 28 § 
ORM + CAR 343 ± 09 310 ± 13 309 ± 11  279 ± 07 § 
LVSP (mmHg)         
CON 101 ± 3 102 ± 3 55 ± 6 * 73 ± 07 § 
CAR  101 ± 3   98 ± 2 55 ± 7 * 88 ± 02 § 
SEA   92 ± 3   90 ± 4 47 ± 6 * 74 ± 05 § 
ORM   96 ± 3   94 ± 7 37 ± 5 * 61 ± 16 § 
SEA + CAR   92 ± 4   94 ± 5 47 ± 6 * 55 ± 12 § 
ORM + CAR   95 ± 3   98 ± 3 39 ± 4 * 90 ± 07 §  
LVEDP (mmHg)         
CON 5.0 ± 1.4 5.0 ± 1.6 5.6 ± 1.6  18.0 ± 4.8 § 
CAR  7.4 ± 1.5 7.8 ± 1.5 8.1 ± 1.2  15.0 ± 3.9 § 
SEA 5.9 ± 0.7 5.4 ± 1.1 6.3 ± 1.3  11.2 ± 6.3 § 
ORM 5.8 ± 0.5 4.3 ± 0.8 5.3 ± 0.9    5.1 ± 0.3 § 
SEA + CAR 5.1 ± 1.1 7.4 ± 2.3 7.4 ± 2.5  15.7 ± 7.4 § 
ORM + CAR 5.5 ± 0.9 4.3 ± 0.9 4.0 ± 0.8  21.1 ± 8.1 § 
DP (mmHg)         
CON  96 ± 3   97 ± 3  55 ± 5 * 55 ± 06 § 
CAR   93 ± 4   90 ± 4  47 ± 7 * 72 ± 06 § 
SEA  86 ± 3   85 ± 5  41 ± 6 * 63 ± 08 § 
ORM  90 ± 3   90 ± 6  32 ± 4 * 61 ± 12 § 
SEA + CAR  85 ± 4   86 ± 6  39 ± 6 * 39 ± 11 § 
ORM + CAR  89 ± 3   94 ± 3  35 ± 4 * 69 ± 08 § 
+dp/dtmax (mmHg/s)         
CON 2678 ± 124 2721 ± 140 1510 ± 147 * 1587 ± 155 § 
CAR  2388 ± 199 2422 ± 186 1344 ± 181 * 2222 ± 238 § 
SEA 2315 ± 176 2361 ± 209 1238 ± 138 * 1583 ± 186 § 
ORM 2691 ± 172 2791 ± 259 1166 ± 113 * 1714 ± 295 § 
SEA + CAR 2666 ± 193 2733 ± 170 1533 ± 170 * 1600 ± 358 § 
ORM + CAR 2191 ± 096 2208 ± 100   975 ± 088 * 1640 ± 208 § 
-dp/dtmax (mmHg/s)         
CON -1942 ± 070 -1963 ± 075 -994 ± 094 * -1150 ± 125 § 
CAR  -1722 ± 151 -1733 ± 113 -966 ± 148 * -1422 ± 098 § 
SEA -1784 ± 093 -1723 ± 127 -938 ± 104 * -1266 ± 120 § 
ORM -2108 ± 113 -2175 ± 171 -891 ± 079 * -1400 ± 296 § 
SEA + CAR -1822 ± 111 -1822 ± 145 -911 ± 116 * -1166 ± 322 § 
ORM + CAR -1825 ± 093 -1891 ± 096 -808 ± 067  -1480 ± 131 § 
  
Table 1. Major hemodynamic variables: coronary flow (CF); heart rate (HR); left ventricular systolic pressure (LVSP); left ventricular
end-diastolic pressure (LVEDP); developed pressure (DP); and contractility (±dp/dtmax) at the end of the control, pretreatment,
ischemia and reperfusion periods. The n number for the first three columns: CON=19; CAR=9; SEA=13; ORM=12; SEA+CAR=12;
ORM+CAR=13; for the reperfusion column: CON=8; CAR=9; SEA=6; ORM=7; SEA+CAR=6; ORM+CAR=5. Significance signs *
and represent P<0.05 compared to the control group for the ischemia (identical n numbers) and reperfusion (different n numbers)
groups, respectively (repeated measure ANOVA).
electrophysiological properties of the heart - the raw values
obtained for the incidence and duration of the ES and VT periods
were highly dependent on the total length of the VF-free periods.
Therefore, in order to provide more realistic information, the
total duration of these periods has been normalised for the total
duration of the VF-free periods. Furthermore, in order to avoid
dividing by zero or close to zero values in cases of very low VF
duration (occurring primarily in cariporide treated hearts),
nominal durations of the VF periods were assigned to score
levels changing in 5 min intervals between 1 and 7 (i.e. VF of
0–5 min corresponded to level 1, 5–10 min to level 2, etc.).
Usually (absolute) incidence means the number of
occurrences (i.e. counts); therefore, it should be dimensionless.
In our analysis, relative incidence values were used, i.e. the
absolute count numbers were normalised to the duration of the
VF-free periods, and therefore expressed as a ratio (the
occurrence divided by the total duration of VF-free periods
during reperfusion). Hence, the dimension of this variable
became frequency (1/min).
Statistical analysis
Statistical calculations were performed using Statistica 9.0
(StatSoft Inc. USA). All data are expressed as means ± S.E.M.
Statistical analysis was performed using parametric or
nonparametric (Kruskal-Wallis) ANOVA, depending on the
homogeneity or inhomogeneity of the variances between
individual groups. All statistical calculations were performed
either relative to the control group (one-way ANOVA) in case of
evaluating the differences between groups with no treatment or
various pharmacological treatments in the same experimental
state (i.e. intergroup differences) or relative to the corresponding
control (non-ischaemic, non-treated) baseline when evaluating
the effect of interventions – i.e. the application of inhibitor(s),
ischaemia or reperfusion (repeated measures ANOVA).
Statistically or marginally significant differences are marked in
figures by * (P<0.05), or # (P<0.1), respectively.
RESULTS
Haemodynamic parameters
Major haemodynamic parameters (CF, HR, LVSP, LVEDP,
DP, and ± dP/dtmax), measured or calculated for all six
experimental groups, in all four phases (control, pre-treatment,
ischaemia, and reperfusion) are summarised in Table 1. Pre-
treatment of the hearts with the vehicle (DMSO), an NCX or
NHE inhibitor, or their combination had no apparent effect on
any of the haemodynamic parameters. Compared to control
values, however, ischaemia induced a large, significant decrease
in CF, LVSP, DP and ± dP/dtmax, while the HR and LVEDP were
practically unchanged. During the reperfusion phase, the CF
recovered, while the LVSP, DP and ± dP/dtmax remained
significantly lower than in the control state. In contrast, LVEDP
became significantly enhanced in all experimental groups.
Nonetheless, is should be emphasised that the n numbers for the
reperfusion data are substantially lower than for all other states.
Importantly and interestingly, using one-way ANOVA, no
significant intergroup differences could be found in values
obtained from the control and test groups during any experiment
phase.
Arrhythmia diagrams
The raw results of the arrhythmia analysis for all
experimental groups are summarised in the graphical
arrhythmia diagram shown in Fig. 1. Following a relatively
short (10 min) period of regional ischaemia, the most common
type of reperfusion-induced arrhythmias evoked in control
(CON) rat hearts (treated solely with the vehicle, DMSO) was
VF. The antiarrhythmic efficacy of the selective NHE inhibitor,
cariporide, at least in this simple model, was excellent.
Compared to the very high incidence of VFs present in the
control group, cariporide treatment drastically reduced the
incidence and even more the duration of reperfusion-induced
arrhythmias. The antiarrhythmic efficacy of the two NCX
inhibitors, SEA0400 and ORM-10103, either alone or in
combination with cariporide, can hardly be quantitatively
estimated by simply looking at the arrhythmia diagram.
Nonetheless, it is obvious that none of these treatments has
been as effective as cariporide treatment alone. In order to
better reveal the relatively moderate but possibly important
differences between various treatments, especially for the two
types of less severe reperfusion induced arrhythmias (ES and
VT), a more detailed, quantitative analysis has been carried out
(see below).
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Fig. 1. Integrated arrhythmia diagram calculated from all hearts. X
axis: reperfusion time; Y axis: arrhythmia diagrams of 78
individual hearts. The hearts were divided into 6 groups: CON
(n=19): control (only vehicle: 0.01mM DMSO); CAR (n=9): 5 µM
cariporide, SEA (n=12): 1 µM SEA0400; ORM (n=12): 1 µM
ORM-10103; SEA+CAR (n=13): 1 µM SEA0400 + 5 µM
cariporide; ORM+CAR (n=13): 1 µM ORM-10103 + 5 µM
cariporide. Each of the horizontal lines represents a single heart.
Time periods with the various arrhythmia stages are shown in
colour: white: regular sinus rhythm (SR); yellow: multiple
extrasystoles (ES); brown: ventricular tachycardia (VT) and red:
ventricular fibrillation (VF).
Quantitative analysis of the incidence and duration during
reperfusion of the sinus rhythm (SR) and the three major types
of arrhythmia (ES, VT and VF)
Average durations of periods with regular sinus rhythm
(SRD) during the 30 min reperfusion phase are summarised in
Fig. 2. The control value (5.26±2.14 min) was calculated from
the unified pool of control rats collected throughout the study.
All further differences were evaluated relative to this control
value.
Cariporide, when used alone, significantly increased the
overall duration of the SR periods during reperfusion (25.8±2.4
min). All other pharmacological treatments were apparently
beneficial, but neither was found to be significant. While in three
of the four groups with an NCX inhibitor, the effect was similar
(10.26±3.89; 10.57±3.61 and 11.25±4.16 min for SEA,
SEA+CAR and ORM+CAR groups, respectively), further to
cariporide, the second largest improvement was achieved in the
group treated with ORM alone (14.86±4.24 min).
The incidence and average duration of the VF periods,
calculated for all groups, are shown in Fig. 3. In control hearts,
both the average duration (VFD) (19.39±3.01 min) and incidence
(VFI) (1.35±0.24 min–1) of VF was high. Furthermore, 11 out of
the 19 hearts utilised in the control group were in the state of
sustained fibrillation at the end of the reperfusion phase.
Compared to the control hearts, cariporide, if used alone,
significantly decreased the incidence (0.55±0.24 min–1) and
particularly the duration (0.25±0.21 min) of the fibrillatory
periods. At the end of reperfusion in this group, none of the 9
hearts was fibrillating. Unlike cariporide, however, the NCX
inhibitors, although exerting a moderate beneficial effect, were
apparently unable to significantly reduce the incidence or
duration of the VF periods. Neither SEA0400 (I: 1.08±0.37
min–1; D: 17.86±4.07 min) nor ORM-10103 (I: 0.80±0.13 min–1;
D: 11.57±4.29 min) could markedly decrease the incidence or
average duration of the VF periods. From this aspect, the overall
anti-VF efficacy of ORM-10103 was slightly more promising.
While no apparent difference could be observed in the number
of hearts with sustained fibrillation (6/12 (ORM-10103)
compared to 7/13 (SEA0400), the duration of the VF periods
was moderately lower in the ORM-10103-treated group
compared to the SEA0400-treated group.
Surprisingly, if cariporide was administered together with an
NCX inhibitor, it failed to improve the moderate anti-VF
protection reached by application of the NCX inhibitor alone
(SEA+CAR, I: 1.07±0.36 min–1; D: 15.67±4.10 min;
ORM+CAR, I: 1.00±0.29 min–1; D: 11.25±3.85 min). These
results suggest that instead of providing enhanced
cardioprotection, the simultaneous application of inhibitors of
the two transporters results in a “loss of action” effect of
cariporide.
The incidence and duration values calculated for periods
with multiple extrasystoles (ESs) are shown in Fig. 4. As
explained in METHODS, in order to more realistically compare the
incidence and duration of the ES (and VT) intervals during the
reperfusion phase, the calculated raw values for each heart were
normalised to the duration of the VF-free periods. With this step,
these variables became independent of the incidence and
duration of the VF periods.
In control hearts, both the incidence (ESI) (0.11±0.02 min–1)
and duration (ESD) (0.14±0.04 min) of the ES episodes was high.
Cariporide, if applied alone, significantly decreased the
incidence (0.03 ± 0.007 min–1) and markedly reduced the
average duration (0.066±0.05 min) of these episodes. The
incidence and especially the duration of the ES episodes were
also significantly reduced by both NCX inhibitors (ESI: SEA:
0.05±0.02 min–1; ORM: 0.05±0.02 min–1; ESD: SEA: 0.02±0.01
min; ORM: 0.02±0.007 min–1). As expected, in the latter case,
the antiarrhythmic efficacy of the NCX inhibitors was
apparently greater than that of NHE inhibition. In contrast, if
applied in combination with an NCX inhibitor, cariporide not
only failed to improve, but virtually eliminated the beneficial
effect of NCX inhibition on the duration and incidence of the ES
episodes (SEA+CAR: 0.11±0.05 min and 0.09±0.03 min–1;
ORM+CAR: 0.17±0.09 min and 0.09±0.02 min–1, respectively).
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Fig. 2. Total duration of periods with
regular sinus rhythm (SRD: min)
during the 30 min reperfusion phase
in all groups. The efficacy of
individual inhibitors and inhibitor
combinations has been evaluated
against the control hearts. * P<0.05,
compared to the control group.
Normalised incidence and average duration values obtained
for the ventricular tachycardia (VT) periods generated during
reperfusion are summarised in Fig. 5. As in other arrhythmia
types, in control hearts, both the incidence (0.17±0.04 min–1) and
average duration (0.14±0.05 min) of the periods with VT were
high. Cariporide treatment provided the most effective anti-VT
protection by dramatically decreasing both the incidence and
duration of the post-ischaemic VT periods (VTI: 0.01±0.002
min–1; VTD: 0.005±0.001 min). However, unlike the ES
episodes, while both NCX inhibitors exerted a moderate
beneficial effect, neither could significantly reduce the incidence
or duration of the VT periods (SEA: 0.16±0.04 min–1 and
0.13±0.05 min; ORM: 0.10±0.03 min–1 and 0.09±0.07 min,
respectively). Furthermore, the simultaneous application of
cariporide and an NCX inhibitor resulted in the almost complete
abolishment of the protection provided by cariporide treatment
alone (SEA+CAR: 0.13±0.06 min–1 and 0.05±0.05 min;
ORM+CAR: 0.09±0.07 min–1 and 0.10±0.05 min).
DISCUSSION
In the present study, the efficacy of two NCX inhibitors, the
fairly selective SEA0400 and the novel, more selective ORM-
10103, against reperfusion-induced arrhythmias were analysed in
detail. Experimental data on the antiarrhythmic effects of
SEA0400 are sparse and contradictory, although mostly positive
(19-22), while similar data for ORM-10103 have become
available only very recently (18, 23, 24). SEA0400 has a moderate
inhibitory effect on the L-type Ca2+ channels (17), while ORM-
10103 has a minor effect on IKr; neither of these pleiotropic effects
could substantially modulate the observed antiarrhythmic efficacy
of the NCX inhibition. Both inhibitors were applied alone or in
combination with a well-characterised selective NHE inhibitor,
cariporide. Cariporide is proposed to be highly selective and to not
influence any of the important ion channels (25-27). It was
assumed that the antiarrhythmic efficacy of a combination of
NCX and an NHE inhibitor would be enhanced.
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Fig. 3. Total duration (VFD: min) and
incidence (VFI: min–1) of periods with
ventricular fibrillation (VF) during the
30 min reperfusion period. Two levels
of significance, has been calculated:
*P<0.05, #P<0.1, compared to the
control group.
Lethal ventricular arrhythmias are among the most common
reasons of high mortality in patients with acute ischaemia-
reperfusion injury. Severe perturbations in intracellular Na+ and
Ca2+ homeostasis leading to gradually elevated [Na+]i and
subsequent [Ca2+]i overload are frequently observed in the
background of the increased incidence of post-ischaemic
ventricular arrhythmias (6). Recent experimental data
demonstrate that these pathological processes are tightly linked
to the abnormal activities of two vital sarcolemmal ion
transporters, the Na+/H+ exchanger and Na+/Ca2+ exchanger, key
effectors of pHi and [Ca2+]i regulation, respectively (3, 4). In the
majority of related experimental studies, the inhibition of one of
these transporters could reduce the incidence and/or severity of
ventricular arrhythmias (9, 10, 21, 28, 29). Therefore, restoring
the normal levels of their activities via pharmacological
intervention is generally considered a highly feasible therapeutic
strategy to prevent, or at least substantially reduce, reperfusion-
induced arrhythmogenesis.
NHE inhibition, as a cardioprotective, antiarrhythmic
strategy, has also been evaluated in a few clinical trials; however,
the routine use of NHE inhibition in human clinical
pharmacology is compromised by the fact that, in contrast to the
highly promising experimental results, relevant human data
obtained from these clinical trials are controversial (11).
Since the data obtained from human trials are not fully
satisfactory, in seems reasonable to assume that combining NHE
inhibition with other protective interventions may substantially
improve its antiarrhythmic efficacy. NCX inhibition is, no doubt,
one of the logical choices, however, this approach was never
explored in details. Indeed, in contrast to the NHE, NCX - in spite
of its obvious significance in pathomechanisms leading to
ischaemia/reperfusion induced arrhythmogenesis - is only
emerging as a possible target for pharmacological intervention
(30). One reason for this apparent delay may be, that while well
established, selective NHE inhibitors have since long been
readily available, until recently experimental efforts to evaluate
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Fig. 4. Relative duration (ESD: min)
and incidence (ESI: min–1) of episodes
with multiple extrasystoles (ESs)
during the reperfusion phase. In order
to better characterise the sensitivity of
the heart to reperfusion-induced VT,
the raw duration (min) and incidence
(min–1) values for each heart were
normalised to the total duration of the
VF-free periods obtained for the same
heart (see the METHODS section for
details). Two levels of significance
were calculated: *P<0.05, #P<0.1,
compared to the control group.
the therapeutic value of NCX inhibition were hampered by the
absence of effective, specific inhibitors, therefore often led to
unclear results (17). Another reason for the lack of adequate
information on the consequences of pharmacological targeting of
NCX in cardiac diseases lies in its complex behavior and poorly
understood physiological regulation - while its transport activities
into both reverse and forward directions are essential for normal
cardiac function, its abnormal activity into any transport direction
may initiate and maintain severe cardiac diseases (4, 31).
For experimental model a widely used arrhythmia protocol
with rather short (10 min) regional ischaemia, induced by LAD
occlusion, followed by a short (30 min) but complete reperfusion
has been selected. An important benefit of this model is that it
provides a rapid experimental procedure to study the
antiarrhythmic efficacy of a drug in a highly reproducible manner.
From the aspect of survival and full recovery to normal sinus
rhythm the critical arrhythmia type in this model is VF. Without
intervention the incidence of VF in control hearts is usually very
high, close to 100% (28), as also has been observed in the
present study (Figs. 1 and 3). Furthermore, though transient
(reversible) VF periods could be often observed, in the majority
of cases with VF, if initiated, became sustained; it did not
terminate spontaneously and the heart was unable to return to
normal SR (32). Further common arrhythmia types, ESs and VT
were also often observed in the present experiments.
The antiarrhythmic efficacy of NHE inhibition has been
evaluated in a number of studies. Pre-ischaemic administration
of cariporide significantly attenuated ischaemia/reperfusion
induced arrhythmogenesis in a variety of in vitro and in vivo
models (26) while its post-ischaemic administration, though
reduced the incidence of VF and subsequent cardiac death, the
effect on mortality was not significant (28, 33, 34). Our results
obtained by the pre-ischaemic application of cariporide reflect
the high antiarrhythmic efficacy of the treatment, and strongly
support the conclusions of similar studies (7-10). As shown in
Figs. 2-5, cariporide significantly increased the duration of the
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Fig. 5. Relative duration (VTD: min)
and incidence (VTI: min–1) of episodes
with ventricular tachycardia (VT)
during the reperfusion phase. Like in
Fig. 4, the raw duration (min) and
incidence (min–1) values for each
heart were normalised to the total
duration of the VF-free periods
obtained for the same heart; *P<0.05,
compared to the control group.
regular sinus rhythm and - with the exception of ESD - all
arrhythmia-related variables were significantly suppressed by
the compound. The high antiarrhythmic efficacy is especially
obvious in the case of VT and VF, since both arrhythmia types
were almost completely eliminated following its application.
The background for the observed high efficacy of cariporide
against VF and VT is not fully clarified. Data from previous
studies indicate that during early reperfusion increased NHE
activity promotes transient shortening of the APD, which renders
the heart susceptible to re-entrant arrhythmias, therefore NHE
inhibition should significantly reduce the susceptibility of the
heart to VF and VT (35). Furthermore, NHE inhibition has been
shown to improve action potential (AP) propagation and reduce
the ischaemia-induced increase in AP dispersion, most probably
via markedly delaying cell-to-cell electrical uncoupling (36).
Since increased AP dispersion is a critical factor in the initiation
and maintenance of VT and VF, improved AP conduction and
subsequently decreased dispersion may be an important
component in the strong anti-VT and -VF effect of cariporide.
In the present study, the antiarrhythmic efficacy of SEA0400
was largely subject to the given arrhythmia type. Its application
effectively reduced the incidence and duration of triggered
arrhythmias (ESs) (Fig. 4), but its efficacy in lengthening the
arrhythmia-free SR periods, preventing initiation and reducing the
duration of VTs and VFs was apparently limited (Figs. 3 and 5).
Compared to SEA0400, the structure of the novel ORM-
10103 is markedly different and its selectivity is enhanced (18).
Regarding its antiarrhythmic effects, when applied alone, ORM-
10103 resembles SEA0400, but its overall efficacy against
triggered arrhythmias (ESs) seems to be even somewhat higher
(Fig. 4). Like SEA0400, it moderately increased the length of
arrhythmia-free periods (slightly more than SEA0400) (Fig. 2),
but unlike SEA0400, it also tended to reduce the incidence and
duration of the VFs and VTs (Figs. 3 and 5). It must be
mentioned, however, that although all of these effects could be
regularly observed, in most cases, for the large standard
deviations, the differences were not significant when using
traditional statistical procedures.
The reasons for the strong arrhythmia-type dependence of
the efficacy of NCX inhibition against reperfusion-induced
arrhythmias are probably complex and may reflect intimate
interactions among a few factors with opposite consequences.
The excellent protection against triggered arrhythmias may be
due to strong inhibition of the reverse NCX transport activity,
leading to a significant reduction in reperfusion-induced Ca2+i
load (37-39), while the lack of a similarly beneficial effect of
SEA0400 on VFs and VTs suggests that to prevent the induction
and maintenance of these arrhythmias, in addition to an effective
reduction of the Ca2+i overload, a similarly effective suppression
of the re-entry activity is also essential (22).
In the present experimental model, VF had by far the largest
contribution to total “arrhythmia time”; thus, its influence on the
outcome of a pharmacological trial is predominant. Regarding
its origin, VF is considered a re-entry type and not triggered-type
arrhythmia; the key factor in its induction and maintenance is
increased AP dispersion and ischaemia/reperfusion-induced
spatial and/or temporal heterogeneities in the resting membrane
potential. Consequently, since NCX inhibition is less suitable to
protect the heart against substrate-induced arrhythmias, it is not
surprising that the efficacy of SEA0400 and ORM-10103 against
VF was also limited in our model. Furthermore, since ischaemia
is short and incomplete in this arrhythmia model, the elevation
of [Ca2+]i during ischaemia and upon reperfusion is probably
moderate, but heterogeneous. Therefore, activation of the
reverse NCX transport mode is probably also moderate but
heterogeneous, and the effect of NCX inhibition on the
ischaemia/reperfusion-induced [Ca2+]i overload in
cardiomyocytes is uneven, unlike how it would be in the case of
a severe, long-lasting ischaemia. Nonetheless, both NCX
inhibitors substantially reduced the overall incidence of Ca2+-
dependent (triggered) arrhythmias, probably originating from
locally injured regions. This finding is in line with most of the
previous studies reporting the marked efficiency of NCX
inhibition in reducing the formation of early and delayed after-
depolarisations (18, 20). Indeed, the significantly higher
efficiency of NCX inhibition may be expected in conditions
where the rise in [Ca2+]I is substantially larger and the Ca2+
overload is more pronounced (e.g. following more extensive,
complete or long-lasting ischaemia).
An unexpected finding of the present study was that
cariporide, when applied simultaneously with any of the NCX
inhibitors, failed to enhance the antiarrhythmic protection
provided by the NCX inhibitor alone. While the effect of
SEA+CAR was practically the same as the effect of SEA alone
during the SR periods, the simultaneous application of
ORM+CAR apparently decreased this parameter (Fig. 2).
Qualitatively, the results obtained for both NCX inhibitors and
all three arrhythmia types were similar: the simultaneous
application of an NHE and an NCX inhibitor did not improve
and eventually worsened the moderate antiarrhythmic efficacy
of the NCX inhibitor alone.
While the results obtained with single inhibitors are logical
and comprehensive, the outcome of the experiments with
simultaneous NHE and NCX inhibition first seems highly
surprising. Indeed, one would expect that the antiarrhythmic
efficacy of simultaneous inhibition should exceed or, at least,
meet the efficacy reached alone by any of the contributors. The
fact that cariporide alone had significantly higher antiarrhythmic
efficacy than in combination with an NCX blocker suggests that
NCX inhibition was an important limiting factor in these groups.
The reason for this apparent restrain is not clear at present and
needs further investigation.
A logical, but largely hypothetical explanation may be as
follows. In these experiments, the antiarrhythmic effect of
cariporide could not be further improved by a synergic effect of
NCX inhibition, since both NHE and reverse NCX inhibition
could prevent the [Na+]i-induced rise in [Ca2+]i. Indeed, this
assumption is supported by the almost identical effects of
combined NCX+CAR and NCX alone inhibition. The decreased
efficiency of cariporide is most probably caused by inactivation
of its beneficial effect on the arrhythmogenic substrate. In other
words, in the combined groups, the NCX inhibitors apparently
exerted a unique anti-antiarrhythmic effect via releasing the
suppressing effect of cariporide treatment and restoring the
susceptibility of the heart to re-entrant arrhythmias. This indirect
proarrhythmic effect is obviously not present if cariporide is
administered alone.
The observed “loss of effect” of cariporide may be related to
the significant inhibition of the forward transport mode of NCX
by SEA0400 or ORM-10103. Indeed, one may speculate that the
beneficial anti-VF effect of cariporide (applied alone) should
manifest in decreasing the spatial and/or temporal
heterogeneities below the critical level required to evoke
fibrillation. Simultaneous inhibition of the forward transport
mode of NCX may exert an opposite effect by increasing these
heterogeneities via inhibiting Ca2+ extrusion needed for
restoration of the normal Ca2+ cycle of the cell. This effect may
be less important in cardiomyocytes affected by a lower level of
ischaemia and subsequent [Ca2+]i load compared to those with
more significant rise in [Ca2+]i. On the other hand, NHE
inhibition may remain latent in normal, non-ischaemic
myocardium, since NHE is mostly inactive at normal pHi, while
NCX inhibition undoubtedly affects Ca2+ handling and AP
kinetics probably differentially in the ischaemic and non-
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ischaemic myocardium. Therefore, the consequence of the
secondary, forward NCX transport mode inhibition may be a
concomitant increase in heterogeneities (eventually shifting
those above the critical level), neutralising the beneficial
blocking effect of cariporide on VFs. To evaluate the validity of
this hypothesis, however, further studies are needed.
Conclusion and perspectives
In principle, inhibition of either the NCX or the NHE and
especially their combined inhibition should effectively protect
the heart against reperfusion-induced harmful arrhythmias, since
both mechanisms target and block the same [Ca2+]i overload
pathway, at different points. The results of this study, however,
are much less straightforward and do not fully support this
presumption. The NHE blocker cariporide, if administered
alone, by also decreasing the incidence and duration of the re-
entrant arrhythmias, provided wider antiarrhythmic efficacy than
when applied simultaneously with an NCX inhibitor, in which
case the probability of VF induction did not differ significantly
from the control. On the other hand, all three inhibitors, alone or
in combination, were found to be effective against triggered
arrhythmias. Therefore, we concluded that NCX inhibition
alone, or in combination with NHE blockade, appears to be a
less than optimal therapeutic strategy against the full range of
reperfusion-induced arrhythmias. A possible reason for the
limited efficacy may be that the currently available selective
NCX inhibitors with their equally effective and long-lasting
bidirectional blockade of the NCX activity are not fully suitable
for this purpose. On the other hand, these NCX inhibitors proved
to be highly effective against EAD- and DAD-induced
arrhythmias (20). To better explore the suggested therapeutic
potential of combined NCX+NHE inhibition, further studies
based on novel NCX inhibitors with different inhibitory
characteristics are needed.
Limitations
An important limitation of the present study is that all three
inhibitors were used at a single concentration. While it is
obvious that a concentration-dependent relationship on the
efficacy of a drug or drug combination could be obtained by
using several concentrations, applying a single, optimally
selected concentration may still satisfactorily characterise its
efficacy. In a number of similar studies (40-46), a single drug
concentration has been utilised to characterise the effect of an
inhibitor on ischaemia-reperfusion injury. In these studies, a
concentration-dependent relationship of the inhibitory effect
has not been explored. Therefore, we are convinced that our
present study will be similarly informative. It should be
emphasised, however, that the selection of an optimal
concentration is, indeed, critical in order to obtain results that
can be considered representative. Therefore, the drug
concentrations used here were selected with extreme care -
especially in the case of NCX inhibitors (e.g. for ORM-10103
EC50 <0.2 µM).
A second limitation of the present study is that the
evaluation of a haemodynamic parameter during the
reperfusion phase may be severely hampered or even
prevented by the presence of an abnormal heart rhythm (VT or
VF), since the correct determination of pressure-related
parameters during abnormal heart rhythm periods is
practically impossible. Therefore, all haemodynamic values
calculated for the reperfusion phase and presented in Table 1
were obtained from hearts devoid of sustained arrhythmias or
were evaluated during a period of sinus rhythm between
arrhythmic periods. Consequently, one should be aware that
while still providing useful information, this analysis may
result in substantial bias, as well, and these data should only
be considered qualitative.
A third important limitation is that the raw values obtained
for the incidence and duration of the ES and VT periods may
strongly depend on the length of VF-free periods. In order to
provide more realistic information, the summed duration of
these periods has been normalised for the summed duration of
the VF-free periods. Although these time-normalised values are
not completely independent of each other, they still appear to
better approximate the duration and incidence of these
arrhythmia types in the VF-free heart.
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